Antiangiogenic therapy with antibodies against VEGF (bevacizumab) or VEGFR2 (ramucirumab) has been proven efficacious in colorectal cancer (CRC) patients. However, the improvement in overall survival is modest and only in combination with chemotherapy. Thus, there is an urgent need to identify potential underlying mechanisms of resistance specific to antiangiogenic therapy and develop strategies to overcome them. Here we found that anti-VEGFR2 therapy upregulates both C-X-C chemokine ligand 12 (CXCL12) and C-X-C chemokine receptor 4 (CXCR4) in orthotopic murine CRC models, including SL4 and CT26. Blockade of CXCR4 signaling significantly enhanced treatment efficacy of anti-VEGFR2 treatment in both CRC models. CXCR4 was predominantly expressed in immunosuppressive innate immune cells, which are recruited to CRCs upon anti-VEGFR2 treatment. Blockade of CXCR4 abrogated the recruitment of these innate immune cells. Importantly, these myeloid cells were mostly Ly6C low monocytes and not Ly6C high monocytes. To selectively deplete individual innate immune cell populations, we targeted key pathways in Ly6C low monocytes (Cx3cr1 −/− mice), Ly6C high monocytes (CCR2 −/− mice), and neutrophils (anti-Ly6G antibody) in combination with CXCR4 blockade in SL4 CRCs. Depletion of Ly6C low monocytes or neutrophils improved anti-VEGFR2-induced SL4 tumor growth delay similar to the CXCR4 blockade. In CT26 CRCs, highly resistant to anti-VEGFR2 therapy, CXCR4 blockade enhanced anti-VEGFR2-induced tumor growth delay but specific depletion of Ly6G + neutrophils did not. The discovery of CXCR4-dependent recruitment of Ly6C low monocytes in tumors unveiled a heretofore unknown mechanism of resistance to anti-VEGF therapies. Our findings also provide a rapidly translatable strategy to enhance the outcome of anti-VEGF cancer therapies. A ntivascular endothelial growth factor (anti-VEGF) therapy is widely used in many types of solid tumors and is the current standard of care for metastatic colorectal cancer (CRC) (1) . However, the beneficial effects from anti-VEGF therapy are often shortlived due to intrinsic resistance and/or resistance acquired during the treatment (1) (2) (3) (4) (5) (6) (7) (8) . Therefore, it is critical to identify mechanisms and/or biomarkers of resistance to target these mechanisms and/or to stratify patients by biomarkers to improve the clinical outcome. We recently found that Ly6C low monocytes infiltrate into tumors in a C-X3-C chemokine receptor 1 (CX3CR1)-dependent manner and confer resistance to anti-VEGFR2 therapy (9) . However, there is no clinically available agent targeting this pathway, which significantly limits the possibility of clinical translation.
We previously reported up-regulation of C-X-C chemokine receptor 4 (CXCR4) and its ligand C-X-C chemokine ligand 12 (CXCL12)-also known as stromal cell-derived factor-1 alpha (SDF-1α)-in primary tumor biopsies from rectal cancer patients treated with the anti-VEGF antibody bevacizumab compared with baseline in the same patients (10, 11) . However, the role of CXCL12/CXCR4 signaling in the resistance to anti-VEGF CRC therapy is not fully understood. While the role of CXCL12/CXCR4
Significance
The survival benefit of antiangiogenic therapies for cancer patients has been limited, potentially due to intrinsic/acquired resistance. Deciphering and targeting resistance mechanisms are critical to improving treatment outcome, especially in cancers where antiangiogenic therapies are standard of care, such as colorectal cancer (CRC). Consistent with our clinical findings, we found up-regulation of CXCL12/CXCR4 in orthotopic CRC models and conditional Apc mutant spontaneous rectal tumors after anti-VEGFR2 treatment. CXCR4 signaling recruited immunosuppressive innate immune cells such as Ly6C low monocytes and Ly6G
+ neutrophils to the CRCs, conferring resistance to VEGFR2 blockade. Furthermore, we successfully targeted these pathways genetically and pharmacologically, including with an FDA-approved agent Plerixafor (AMD3100), which significantly enhanced treatment response. These strategies have the potential for rapid clinical translation.
axis in regulation of immune cells has been investigated, including a subset of monocytes (i.e., Ly6C high monocytes) (12) (13) (14) (15) (16) (17) , whether CXCR4 is involved in regulation of another subset of monocytes (i.e., Ly6C low monocytes) is not known. In this study, building on our previous clinical finding that CXCR4 is up-regulated in rectal cancer postbevacizumab therapy, we targeted CXCR4 using AMD3100, an FDA approved agent, which resulted in significant improvement of anti-VEGFR2 therapy in clinically relevant orthotopic murine CRC models. Mechanistically, we found that CXCR4 is critical for tumor infiltration of Ly6C low monocytes and that blockade of Ly6C low monocyte recruitment improves the efficacy of anti-VEGFR2 therapy in CRCs. Thus, targeting CXCR4-mediated Ly6C low monocyte infiltration is a potential strategy to enhance the efficacy of anti-VEGF treatments for CRC patients.
Results
Antiangiogenic Therapy Increases Expression of CXCL12 and CXCR4 in CRCs. We treated two different orthotopic colon cancer models-SL4 and CT26-as well as a spontaneous rectal tumor model in Apc conditional knockout mice with a monoclonal antibody (DC101) targeting VEGF receptor 2 (VEGFR2) (18) . We have previously demonstrated that CXCL12 and CXCR4 expression increases in primary human rectal tumors of patients treated with bevacizumab monotherapy (10, 11) . Consistent with these clinical data (11), we found a significant increase in CXCR4 and CXCL12 expression after DC101 treatment in both spontaneous rectal tumors and established CRCs ( Fig. 1 A-D and Fig. S1 ). These findings indicate that our CRC models recapitulate the response of primary human CRCs to bevacizumab.
Blockade of CXCR4 Enhances the Antitumor Effect of Anti-VEGFR2
Therapy. We next examined the role of CXCL12/CXCR4 signaling in the resistance to anti-VEGFR2 therapy in CRCs using an FDA-approved CXCR4 inhibitor (AMD3100) (19) . In both SL4 and CT26 models, we found that treating with AMD3100 significantly enhanced the antitumor effect of anti-VEGFR2 (DC101) therapy, resulting in delayed tumor growth and increased survival of animals ( Fig. 1 E-H and Figs. S2-S4). Interestingly, SL4 tumors were more sensitive to DC101 therapy than CT26 tumors, representing the heterogeneity in patient response. As we have previously shown (9), SL4 and CT26 tumor size was ∼45% and ∼70% of that of the control after 12 d of DC101 monotherapy ( Fig. 1 G and H) . In addition, the extent of tumor growth inhibition by the combined therapy was similar in both SL4 and CT26 models. These data indicate that the mechanism making CT26 less sensitive to anti-VEGFR2 treatment was abolished by the blockade of CXCR4. These data show that targeting CXCR4 enhances the efficacy of antiangiogenic therapy in both CRC models, regardless of their sensitivity to anti-VEGFR2 monotherapy.
Blockade of CXCR4 Alleviates Anti-VEGFR2 Therapy-Induced Lymphocyte
Reduction but Does Not Directly Affect Tumor Cell Proliferation. Next, we sought the mechanisms of how the blockade of CXCR4 enhances the antitumor effect of anti-VEGFR2 therapy. First, we tested whether the blockade of CXCR4 directly inhibited proliferation of cancer cells themselves. MTT (methyl thiazolyl tetrazolium) assay results showed that CXCR4 is not involved in the regulation of colon cancer cell proliferation (Fig. S5) . Given the important role of CXCR4 in chemotaxis of leukocytes (20, 21) , we next examined the effect of AMD3100 and DC101 on the immune microenvironment. We analyzed lymphoid populations in SL4 and CT26 tumors and found fewer CD4 + (SL4, 3.7 ± 0.8% in control vs. 1.7 ± 0.3% in DC101 and CT26, 4.4 ± 0.9% in control vs. 2.5 ± 0.4% in DC101) and CD8
+ T cells (SL4, 4.1 ± 0.8% in control vs. 2.3 ± 0.7% in DC101 and CT26, 8.9 ± 1.7% in control vs. 4.1 ± 1.2% in DC101) in the DC101-treated group (Fig. S6 ). We also found that AMD3100 treatment restored the number of T lymphocytes to the level of control rat IgG-treated tumors (Fig. S6 ).
Given that effector CD4
+ and CD8 + T cells are known to express CXCR4 in some contexts (22, 23) , we measured the expression of CXCR4 on these lymphocytes. However, to our surprise, we observed only a negligible level of CXCR4 expression on T lymphocytes in the CRC microenvironment (Fig. S7 ). Based on these findings, we explored whether the effect of AMD3100 treatment on the inhibition of T-cell infiltration is indirect and mediated by other immune cell types expressing CXCR4. One week after treatment, CXCR4 and CXCL12 mRNA expression levels in CRCs were determined by quantitative real-time PCR, normalized against GAPDH. Data are presented as mean ± SEM n = 5 per group. *P < 0.05 vs. control. (C and D) Gene expression levels for Cxcr4 (C) and Cxcl12 (D) in CT26 tumor. CT26 tumors in BALB/c wild-type mice were treated with either IgG control (C) or monoclonal anti-VEGFR2 antibody, DC101 (40 mg/kg, every 3 d). One week after treatment, relative CXCR4 and CXCL12 mRNA expression levels in CRCs were determined by quantitative realtime PCR, normalized against GAPDH. n = 5 per group. *P < 0.05 vs. control. **P < 0.04 vs. control. ***P < 0.03 vs. control. (E) SL4 tumor burden was assessed by blood Gluc activity measurement (53) . Data are represented as mean ± SEM n = 8 per group. (F) CT26 tumor volume was measured using a high-frequency ultrasound imaging system (3). Data are represented as mean ± SEM n = 8 per group. *P < 0.05 vs. corresponding control. populations in CRC tissues upon DC101 treatment (Fig. S7) . Consistent with these findings and our previous studies in other types of tumors (24), we observed an increase in CD11b + Gr1 + cells in DC101-treated tumors shown by flow cytometry (Fig. S8) 
Gr1
+ cells were previously implicated in resistance to anti-VEGF therapy (2, 25) . We also found abundant expression of CXCR4 in another monocyte subsetLy6C low monocytes-which do not belong to the CD11b + Gr1 + myeloid cells (Fig. S7 ). Of note, these myeloid cells are devoid of F4/80 and CD11c expression. Hence, they do not appear to be tumor associated macrophages (TAMs) or dendritic cells (DCs) (Fig. S9) .
Blockade of CXCR4 Inhibits Anti-VEGFR2 Therapy-Induced Tumor Infiltration of Ly6C low Monocytes and Ly6G
+ Neutrophils. We have previously analyzed these three different myeloid cell subpopulations expressing CXCR4 (i.e., Ly6C low monocytes, Ly6C high monocytes, and Ly6G + neutrophils) during the course of anti-VEGFR2 therapy (9) . Consistent with our prior work, we found DC101 treatment significantly increased the number of Ly6C low monocytes on day 5 and day 12 ( Fig. 2 ) in SL4 and CT26 tumors. Also, there was a significant increase in the number of neutrophils on day 12 after DC101 treatment in both tumor models ( Fig. 2 B and D) . The number of Ly6C high monocytes was much lower than the other two subpopulations and did not change upon anti-VEGFR2 therapy (Fig. 2) . In addition, the fractions of Ly6C low monocytes and Ly6G
+ neutrophils to CD45 + cells were higher in CT26 than in SL4 tumors after DC101 treatment, which seems consistent with the differences in growth behavior of CT26 ("DC101 resistant" as shown in Fig. 1 F and H) and SL4 tumors ("DC101 sensitive") (Fig. 1 E and G) .
In both SL4 and CT26 tumors, consistent with our previous findings (9), we observed that Ly6C low monocytes infiltrate into tumors before neutrophils (Fig. 2) . Furthermore, AMD3100 treatment inhibited DC101-induced Ly6C low monocyte and neutrophil accumulation (Fig. 2 B and D) , which is consistent with our hypothesis and leads to the improved antitumor efficacy that we observed ( Fig. 1 E and F) .
In
Efficacy of Anti-VEGFR2 Therapy. Next, we performed a series of experiments depleting individual subsets of myeloid cells. Ly6C low monocytes express a high level of CX3CR1, and their infiltration is dependent on this chemokine receptor (26) (27) (28) . We specifically inhibited the infiltration of Ly6C low monocytes by using Cx3cr1
−/− mice as described previously (9, 29, 30) . Using Cx3cr1 −/− mice, we also confirmed our earlier observation of impaired recruitment of Ly6G + neutrophils, which arrive after Ly6C low monocytes (9) (Fig.  S10) . DC101 monotherapy in wild-type mice exhibited modest tumor growth delay and survival benefit (Fig. 3A and Fig. S4A ). AMD3100 treatment in combination with DC101 in wild-type mice showed a further improvement in antitumor efficacy (Fig. 3A  and Fig. S4A ). The antitumor efficacy of combinatorial treatment of AMD3100 and DC101 in wild-type mice was comparable to that of DC101 monotherapy in Cx3cr1 −/− mice (Fig. 3A) . However, there was no further improvement in antitumor efficacy by AMD3100 treatment in Cx3cr1 −/− mice (Fig. 3A) . Using Ccr2 −/− mice to specifically inhibit infiltration of Ly6C high monocytes, there was no difference in antitumor efficacy from any of the tested treatments between wild-type and Ccr2 −/− mice (Fig. 3B) . Lastly, using an anti-Ly6G neutralizing antibody to deplete neutrophils, antitumor efficacy was improved when combined with DC101 (Fig.  3C) , similar to the effect of combined AMD3100 and DC101.
In Anti-VEGFR2-Resistant CT26 Tumors, Blockade of both Ly6C low
Monocyte and Ly6G
+ Neutrophil Infiltration Is Needed to Improve the Efficacy of Anti-VEGFR2 Therapy. As shown, CT26 tumors are more refractory to anti-VEGFR2 ( Fig. 1 E and F) and have a higher number of Ly6C low monocytes than SL4 tumors (Fig. 2) . Thus, we asked whether the inhibition of neutrophil infiltration in CT26 tumors is sufficient to improve the efficacy of anti-VEGFR2 therapy as observed in SL4 tumors (Fig. 3C) . We used anti-Ly6G antibody to specifically deplete neutrophils in the CT26 model. Interestingly, even with the successful depletion of neutrophils after anti-Ly6G antibody treatment, we did not observe any significant improvement in antitumor efficacy from the combination treatment of DC101 and anti-Ly6G antibody compared with DC101 monotherapy (Fig. 4) . Meanwhile, when we treated AMD3100 along with DC101, there was a dramatic enhancement in antitumor efficacy compared with DC101 monotherapy in CT26 tumors (Fig. 4 and Fig. S4B ). Thus, we conclude that blockade of CXCR4-which efficiently inhibits infiltration of both Ly6C low monocytes and neutrophils-is more effective than targeting neutrophils alone. Therefore, it is critical to target Ly6C low monocytes to improve anti-VEGFR2 therapy efficacy especially in CRCs highly refractory to the treatment.
Discussion
In this study, we first verified that the findings from our preclinical CRC models recapitulate the key findings of our previous clinical studies on CRC patients with anti-VEGF therapynamely up-regulation of CXCL12/CXCR4 pathway after a single dose of bevacizumab (31) . Our preclinical models allowed a causal study of this signaling pathway using a clinically available CXCR4 inhibitor (AMD3100). Furthermore, we found that targeting Ly6C low monocytes is essential to improve antitumor efficacy of anti-VEGFR2 therapy in tumors highly resistant to the therapy, such as CT26. The elevated numbers of Ly6C low monocytes in CT26 tumors may explain, at least in part, why CT26 tumors are more resistant than SL4 tumors to anti-VEGF therapy and why blocking neutrophils using anti-Ly6G antibody was not sufficient to improve the antitumor efficacy of DC101 treatment (Fig. 4) . Importantly, as AMD3100 targets both Ly6C low monocytes and neutrophils, these findings suggest a possible route for clinical translation for improving antiangiogenic treatment of colorectal cancer therapy.
There have been several reports showing that TAMs mediate resistance to anti-VEGF therapy in different types of cancers (2, 32) . It is also known that VEGF inhibition promotes maturation and activation of DCs, which leads to an increase in intratumoral effector T-cell numbers (5) . In this study, we found Ly6C low monocytes are the key players that drive resistance to anti-VEGFR2 therapy in colorectal cancer.
We have previously found reduced blood vessels after anti-VEGFR2 therapy (9) , which indicates that alternative angiogenesis mechanisms are not the chief cause of CRC resistance to anti-VEGFR2 therapy. We have also found progressively increased hypoxia in parallel with the decrease in the intratumoral vessel density in these CRCs over the course of DC101 treatment compared with the control (9) . It has been shown that antiangiogenic treatment up-regulates the expression of CXCL12 in tumors via hypoxia (1). Indeed, the protein level of CXCL12 increased on days 5 and 12 in proportion to the degree of hypoxia (Fig. S1C) . CXCL12 is also produced by tumorinfiltrating Ly6C low monocytes and Ly6G + neutrophils (9) . We also found a predominant expression of CXCR4 in CD11b + monocytes and neutrophils compared with the lymphoid populations-as measured by flow cytometry (Fig. S7) . Thus, DC101 treatment appears to trigger a positive feedback loop between the expression of CXCL12 and the infiltration of CXCR4-expressing Ly6C low monocytes and Ly6G + neutrophils in CRCs.
Here, we showed that the blockade of CXCR4 significantly improves antitumor efficacy when combined with antiangiogenic therapy. Blockade of CXCR4 with AMD3100 treatment significantly inhibited DC101-induced tumor infiltration of Ly6C low monocytes and neutrophils in both SL4 and CT26 tumors. However, AMD3100 treatment did not completely abolish infiltration of Ly6C low monocytes and neutrophils. This could possibly be due to the fact that some Ly6C low monocytes and neutrophils are recruited to tumors in a CXCR4-independent manner or that the dose we used to block CXCR4 signaling is not sufficiently high. Nevertheless, the majority of Ly6C low monocytes and neutrophils infiltrate into the tumor in a CXCR4-dependent manner, and their infiltration can be efficiently blocked by targeting the CXCR4 axis. It would be of interest to further characterize the CXCR4-independent Ly6C low monocytes and neutrophils and/or to examine the effect of a higher dose of AMD3100 on the infiltration of these cells in future studies.
Recently, we found that Ly6C low monocytes and neutrophils infiltrate into tumors and confer resistance to anti-VEGFR2 therapy by secreting high amounts of immunosuppressive cytokines such as IL-10. These immunosuppressive cytokines inhibit adaptive immunity in the tumors, characterized by low numbers of CD4 + and CD8 + T cells as well as their dysfunctional phenotype (i.e., increased PD-1 + and reduced Granzyme B expression) (9) . Consistent with this, we observed the restoration of CD4 + and CD8 + T cells and tumor growth delay when we added AMD3100 treatment to DC101 treatment. It should be noted that the expression levels of CXCR4 on CD4
+ and CD8 + T cells are very low, while CXCR4 is highly expressed in the Ly6C low monocytes and Ly6G
+ neutrophils (Fig. S7) . While the blockade of CXCR4 signaling lowers the infiltration of these immunosuppressive myeloid cells and restores adaptive immune cells, the depletion of these Ly6C low monocytes and neutrophils in the absence of CXCR4 blockade can also restore the number of adaptive immune cells completely (9) . These findings suggest that, while the restoration of CD4 + and CD8 + T cells and their function after AMD3100 treatment results in tumor growth delay (Figs. 3 and  4) , the effect on adaptive immune cells seems to be indirectly through monocytes and neutrophils via immunosuppressive cytokines such as IL-10.
The immune system plays an important role in any cancer treatment directly or indirectly (33) (34) (35) (36) (37) (38) (39) . Recently, cancer immunotherapy using immune checkpoint blockers (ICBs) has revolutionized cancer therapy by curing some patients (40) (41) (42) . However, the majority of cancer patients do not respond to ICBs, even in the most promising indications (41, 43) . In the case of CRCs, the success of ICBs is limited to a small portion of patients with high microsatellite instability or mismatch repairdeficient cancers (44, 45) . Therefore, there is an urgent need to identify intrinsic and/or acquired immunosuppression mechanisms causing resistance to ICBs and to develop novel immunotherapeutic strategies targeting such resistance mechanisms. There is mounting evidence showing that innate immune cells are actively involved in the development and progression of many types of cancers, albeit with different functions in each cancer (4, 5, (46) (47) (48) (49) (50) . These innate immune cells are also known to play a critical role in resistance to anti-VEGF therapy in some types of cancers (2, 4). As we have shown here, the role of protumorigenic Ly6C low monocytes and neutrophils in CRCs and various other types of cancers in the setting of antiangiogenic therapy in combination with ICBs should be explored further.
Collectively, we established a critical causal role of CXCR4 signaling in conferring resistance to anti-VEGFR2 therapy by recruiting Ly6C low monocytes and Ly6G + neutrophils to tumors and thereby skewing CRCs toward an immunosuppressive phenotype (e.g., IL-10 expression and dysfunctional cytotoxic T lymphocytes). Furthermore, we successfully inhibited recruitment of these innate immune cells by targeting the responsible pathways pharmacologically with the FDA-approved CXCR4 blocker AMD3100, which significantly extended treatment response in clinically relevant animal models of colon cancer.
Experimental Procedures
Spontaneous Rectal Tumor Model and CRC Cell Preparation for Orthotopic CRC Models. Before implantation, we cultured SL4 (51) murine CRC cells in DMEM/ F12 medium containing 10% FBS. We cultured CT26 (52) murine CRC cells in RPMI-1640 medium containing 10% FBS. We harvested subconfluent CRC cells (i.e., SL4 or CT26), and then washed the harvested cells with PBS, followed by counting the number of cells. We mixed the tumor cell suspension with the same volume of Matrigel (product no. 354262, Corning). For orthotopic SL4 CRC model, we intraperitoneally injected 100 mg/kg of ketamine and 10 mg/kg of xylazine to anesthetize 8-to 10-wk-old C57BL/6 mice. For orthotopic CT26 CRC model, we intraperitoneally injected 100 mg/kg of ketamine and 10 mg/kg of xylazine to anesthetize 8-to 10-wk-old BALB/c mice. We then removed abdominal hair using a hair clipper and made a 10-mm-long midline incision. Through the incision we exteriorized the cecum, and then injected 10 μL of cell/Matrigel mixture containing 5 × 10 5 cells from the serosal side into the cecum wall between the mucosa and serosa. We used a 27-gauge needle with an insulin syringe for the cell/Matrigel mixture injection (51, 52) . We put back the cecum to the abdominal cavity, closed the abdominal wall with 5-0 polysorb sutures (Covidien), and closed the skin using surgical staples. We monitored tumor size by assessing blood Gaussia luciferase (Gluc) activity (53, 54) or by using a high-frequency ultrasound imaging system two times a week. We used Apc conditional knockout mice as we previously described (18) for spontaneous rectal tumor model. All animal procedures followed NIH Public Health Service Policy on Humane Care and Use of Laboratory Animals and were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee.
Blood Gluc Assay for Monitoring SL4 Tumor Growth. We transduced SL4 cells with lentivirus encoding the Gluc gene to generate the SL4-Gluc cell line. We measured the activity of secreted Gluc to monitor SL4 tumor growth as described previously (53, 54) . We collected blood from the tumor-bearing mice every 2 or 3 d. We used a GloMax 96 Microplate Luminometer (Promega) to measure the blood Gluc activity.
Ultrasound Imaging. We monitored tumor growth by using a high-frequency ultrasound imaging system two times a week (Vevo 2100 system, VisualSonic) using a probe with a 40-MHz frequency (MS550S) (3). We intraperitoneally injected 100 mg/kg of ketamine and 10 mg/kg of xylazine to anesthetize mice and kept them on a heated platform. We then removed abdominal hair using a hair clipper and applied ultrasound gel on the skin. We identified tumor in the cecum as a low echoic mass and acquired images using the MS550S probe. We measured the long diameter (LD) and short diameter (SD) from the images and calculated tumor volume as (LD × SD 2 )/2. Flow Cytometry. We performed flow cytometry as described previously (55) . We harvested tumor tissues and chopped using a surgical scissor. We incubated chopped tissue with digestion medium containing 1.5 mg/mL of collagenase type 1A, 1.5 mg/mL of hyaluronidase, and 2 mg/mL of DNase for 1 h in a 37°C incubator. We filtered the digested tissue using 70-μm cell strainers followed by filtering with 40-μm cell strainers. We incubated single cell suspensions for blocking with an anti-mouse CD16/CD32 antibody. We then stained the cell suspensions with the following antibodies: CD45 (clone 30-F11), B220 (clone RA3-6B2), CD49b (clone DX5), CD90 (clone 53-2.1), NK1.1 (clone PK136), Ter119 (clone TER-119), I-A/I-E (clone M5/114.15.2), CD4 (clone RM4-5), CD8 (clone 53-6.7), CD25 (clone PC61), FoxP3 (clone FJK-16s), CD11b (clone M1/70), F4/80 (clone BM8), CD11c (clone HL3), Gr1 (clone RB6-8C5), Ly6C (clone HK1.4), and Ly6G (clone 1A8) (BD Biosciences). We added 7-amino-actinomycin D (7AAD) reagent (eBioscience) to the stained tubes to rule out dead cells just before running flow cytometry. Monocytes were defined as CD45 
